Glox Therapeutics has named Dr Michael Murray as its new Chair.
Dr Michael Murray is the Principal at Murray International Partners, and has led multiple high-value international deals in the life sciences sector using his scientific expertise and skills.
These extend into intellectual property management, market assessment and deal making, which he has used to support universities, start-ups, SMEs, mid-cap companies and multinationals.
He has nearly 30 years’ experience in senior and interim management roles at several biotech/pharma companies, including Metallobio, Porton Biopharma, EnteroBiotix, Sosei Heptares and Amura Therapeutics, as well as an international commercial consultancy practice.
He teaches commercial IP strategy on the Novo Nordisk Fellowship MBA in BioMedical Design programme (Denmark) and has delivered training to over 1,200 individuals in the commercialisation of technical innovations since 2015.
Dr Murray is also a Member of The Royal Society Industry College, an Entrepreneur in Residence at the University of Sheffield, where he was a Royal Society Entrepreneur in Residence from 2019–2022, a Mentor at Cambridge Enterprise and, from 2017 until last year, was a Member of both the Research Strategy Board and the Commercialisation Committee of Coeliac UK.
He is also a Registered Technology Transfer Professional and a Member of the International Technology Transfer Network (China).
Dr Moore joins scientific board
Dr Nel Moore will also join the company's scientific advisory board.
Formerly the VP of Antibiotics Development at AstraZeneca, Dr moore has gained vast experience in drug discovery, development and commercialisation throughout her 21 year career.
At AstraZeneca, she led the late-stage development of Zavicefta™/Avycaz™ for the treatment of multidrug-resistant bacterial infections — which subsequently gained approval from regulatory boards across the globe.
She went on to build and lead AstraZeneca’s antibiotics development organisation, supporting four antibiotics in various stages of development and commercialisation, before its divestment to Pfizer.
Since 2018, she has been supporting biotech companies with strategic planning, implementation and execution of business plans, and fundraising in her role as a senior R&D consultant at FWEast and non-executive director.
She is currently, also an Independent Council Member at Aston University and Executive Chair/CEO of CHAIN Biotechnology. Dr Moore holds a PhD in Biochemistry from the University of Birmingham and currently sits on several CARB-X Advisory Boards.
Dr James Clark, CEO and Co-founder, Glox Therapeutics, said: “Drs Murray and Moore have an outstanding track record in their respective fields. We are delighted to welcome both of these eminent individuals on board as we continue to drive expansion and strengthen our team. Their commercial expertise and unique research perspectives will be an invaluable strategic resource as we stride towards our goal to create potent, species-specific antibiotics that combat AMR.”